ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
Revenue
ADC Therapeutics SA
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ADC Therapeutics SA
NYSE:ADCT
|
Revenue
$69.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
129%
|
CAGR 10-Years
N/A
|
|
AC Immune SA
NASDAQ:ACIU
|
Revenue
CHf14.8m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Revenue
$371.2m
|
CAGR 3-Years
709%
|
CAGR 5-Years
160%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Revenue
CHf157.6m
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
14%
|
|
Idorsia Ltd
SIX:IDIA
|
Revenue
CHf97.1m
|
CAGR 3-Years
60%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Kuros Biosciences AG
SIX:KURN
|
Revenue
CHf33.6m
|
CAGR 3-Years
103%
|
CAGR 5-Years
116%
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Revenue?
Revenue
69.6m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Revenue amounts to 69.6m USD.
What is ADC Therapeutics SA's Revenue growth rate?
Revenue CAGR 5Y
129%
Over the last year, the Revenue growth was -67%.